GCP
ARQT icon

GSA Capital Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

GSA Capital Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
46,087
+33,962
+280% +$867K 0.07% 447
2025
Q4 		$352K Sell
12,125
-21,567
-64% -$552K 0.03% 1076
2025
Q3 		$635K Buy
33,692
+18,017
+115% +$284K 0.05% 685
2025
Q2 		$220K Sell
15,675
-6,231
-28% -$87.4K 0.02% 1460
2025
Q1 		$343K Buy
+21,906
New +$309K 0.03% 1052
2024
Q4 		– Sell
-237,174
Closed -$2.21M – 1590
2024
Q3 		$2.21M Buy
237,174
+208,599
+730% +$2.06M 0.17% 97
2024
Q2 		$266K Sell
28,575
-7,973
-22% -$72.1K 0.02% 1330
2024
Q1 		$362K Sell
36,548
-38,306
-51% -$286K 0.03% 1096
2023
Q4 		$242K Buy
+74,854
New +$203K 0.02% 1225
2022
Q2 		– Sell
-27,851
Closed -$536K – 1383
2022
Q1 		$536K Buy
+27,851
New +$471K 0.07% 478

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return